Filing Flows › Royalty Pharma (RPRX) › Q3 2026 › vs Q2 2026
Royalty Pharma (RPRX) Q3 2026 vs Q2 2026 (quarter over quarter)
Royalty Pharma's revenue rose $16.0M (+2%) from $674M in Q2 2026 to $690M in Q3 2026. The biggest changes: Income from financial royalty assets +$9.6M (+2%); Other royalty income and revenues +$6.4M (+18%). Operating margin 59.5% against 19.7% (+39.8 pts).
Royalty Pharma, Q3 2026: revenue $690M (+13% year over year), operating margin 59.5%, net earnings $145M, operating cash flow $686M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 59.5% | 19.7% | +39.8 pts |
| Net margin | 21.0% | 2.7% | +18.3 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Income from financial royalty assets | $648M | $638M | $9.6M | +2% |
| Other royalty income and revenues | $42.5M | $36.1M | $6.4M | +18% |
| Revenue | $690M | $674M | $16.0M | +2% |
| Operating profit | $411M | $133M | $278M | +209% |
| Costs & expenses | $279M | $541M | −$262M | -48% |
| Pre-tax earnings | $267M | $81.5M | $185M | +227% |
| Other expense, net | $144M | $51.6M | $92.6M | +179% |
| Research & development | $63.2M | $97.9M | −$34.7M | -35% |
| General & admin | $150M | $162M | −$11.8M | -7% |
| Other operating costs | $66.0M | $281M | −$215M | -77% |
| Net earnings | $145M | $17.9M | $127M | +709% |
| Minority interests | $122M | $63.6M | $58.4M | +92% |
| Depreciation | $1.2M | $1.3M | −$73K | -6% |
| Share-based compensation | $105M | $107M | −$2.2M | -2% |
| Working capital & other | $435M | $602M | −$167M | -28% |
| Operating cash flow | $686M | $728M | −$42.4M | -6% |
Questions
How much did Royalty Pharma's revenue grow quarter over quarter in Q3 2026?
Royalty Pharma's revenue rose $16.0M (+2%) from $674M in Q2 2026 to $690M in Q3 2026.
What drove Royalty Pharma's revenue change in Q3 2026?
Income from financial royalty assets +$9.6M (+2%); Other royalty income and revenues +$6.4M (+18%).